Skip to main content
. 2002 Jun;46(6):1723–1727. doi: 10.1128/AAC.46.6.1723-1727.2002

TABLE 2.

Antifungal susceptibility of Candida isolates stratified by species and fluconazole susceptibility

Species (n) Antifungal agent Fluconazole susceptibilitya
S
S-DD
R
All
n MIC50/MIC90 %S n MIC50/MIC90 %S n MIC50/MIC90 %S n MIC50/MIC90 %S
C. albicans (4,195) Fluconazole 4,054 0.25/0.5 100 56 16/32 0 85 >128/>128 0 4,195 0.25/0.5 97
Itraconazole 0.03/012 96 0.5/1 11 1/>8 0 0.03/0.12 93
Voriconazole 0.007/0.015 99 0.25/1 93 1/>8 57 0.007/0.03 99
Ravuconazole 0.007/0.015 99 0.25/2 89 0.25/>8 73 0.007/0.03 99
Amphotericin Bb 0.5/1 96 1/2 85 1/2 79 0.5/1 95
5FC 0.5/1 97 0.25/1 96 0.25/1 98 0.25/1 97
C. glabrata (949) Fluconazole 567 4/8 100 303 16/32 0 78 >64/>64 0 949 8/32 60
Itraconazole 0.5/1 6 1/2 0 8/>8 0 1/2 4
Voriconazole 0.12/0.25 100 0.5/1 97 2/8 13 0.25/1 92
Ravuconazole 0.12/0.5 99 0.5/2 87 4/8 11 0.25/2 89
Amphotericin B 2/4 46 2/4 46 1/4 57 2/4 47c
5FC 0.12/0.12 99 0.12/0.12 98 0.12/0.12 97 0.12/0.12 99
C. parapsilosis (814) Fluconazole 803 0.5/2 100 8 16/NDd 0 2 64/ND 0 814 0.5/2 99
Itraconazole 0.12/0.25 55 0.5/ND 0 0.25/ND 0 0.12/0.25 4
Voriconazole 0.03/0.06 100 0.5/ND 71 0.5/ND 100 0.03/0.06 99
Ravuconazole 0.03/0.12 100 1/ND 71 0.12/ND 100 0.03/0.12 99
Amphotericin B 2/4 42 1/ND 60 1/ND 50 2/4 43c
5FC 0.12/0.25 99 0.12/ND 100 0.25/ND 50 0.12/0.25 99
C. tropicalis (597) Fluconazole 585 0.5/2 100 7 16/ND 0 5 >64/ND 0 597 0.5/2 98
Itraconazole 0.12/0.5 59 1/ND 0 >8/ND 0 0.12/0.5 58
Voriconazole 0.03/0.12 100 1/ND 50 >8/ND 0 0.06/0.12 99
Ravuconazole 0.03/0.12 99 2/ND 33 >8/ND 0 0.03/0.12 98
Amphotericin B 1/2 57 1/ND 50 1/ND 50 1/2 57c
5FC 0.5/1 93 0.25/ND 100 0.5/ND 100 0.25/1 93
C. krusei (131) Fluconazole 6 8/ND 100 65 32/32 0 60 64/64 0 131 32/64 5
Itraconazole 0.25/ND 17 0.5/1 2 1/1 2 0.5/1 2
Voriconazole 0.12/ND 100 0.25/0.5 100 0.5/1 98 0.5/0.5 99
Ravuconazole 0.25/ND 100 0.25/0.5 98 0.5/1 98 0.5/0.5 98
Amphotericin B 1/ND 50 4/8 6 4/8 2 4/8 7c
5FC 0.25/ND 67 16/32 5 16/32 2 16/32 6
C. dubliniensis (88) Fluconazole 78 0.12/0.25 100 6 32/ND 0 4 >64/ND 0 88 0.25/16 89
Itraconazole 0.06/0.12 91 0.12/ND 50 0.5/ND 0 0.06/0.25 84
Voriconazole 0.007/0.03 100 0.25/ND 100 0.5/ND 100 0.007/0.03 100
Ravuconazole 0.007/0.03 100 0.06/ND 100 0.06/ND 100 0.007/0.03 100
Amphotericin B 1/1 100 0.12/ND 100 0.5/ND 100 0.25/0.5 100
5FC 0.06/0.06 100 0.06/ND 100 0.06/ND 100 0.06/0.06 100
C. guilliermondi (85) Fluconazole 68 4/8 100 14 16/32 0 2 >64/ND 0 85 4/16 81
Itraconazole 0.5/1 7 1/1 0 4/ND 0 1/1 7
Voriconazole 0.12/0.25 100 0.25/0.5 100 2/ND 0 0.12/0.25 98
Ravuconazole 0.25/0.5 97 0.5/1 100 4/ND 0 0.25/1 98
Amphotericin B 0.25/1 100 0.5/1 100 0.5/ND 50 0.5/1 99
5FC 0.12/0.5 100 0.12/0.25 100 0.06/ND 100 0.12/0.5 100
C. lusitaniae (58) Fluconazole 57 0.5/2 100 1 16 0 58 0.5/2 98
Itraconazole 0.12/0.25 51 2 0 0.12/0.25 50
Voriconazole 0.007/0.015 100 0.5 100 0.007/0.015 100
Ravuconazole 0.015/0.06 100 2 0 0.015/0.06 98
Amphotericin B 0.5/1 98 0.5 100 0.5/1 98
5FC 0.06/0.12 91 0.06 100 0.06/0.12 93
a

Fluconazole susceptibility categories are defined in the footnote to Table 1. n represents the number of isolates tested in each category. %S, percent susceptible: fluconazole MIC, ≤8 μg/ml; 5FC MIC, ≤4 μg/ml; itraconazole MIC, ≤0.12 μg/ml; all other MICs, ≤1 μg/ml.

b

Amphotericin B MICs were determined by Etest.

c

P < 0.001 compared to amphotericin B activity against C. albicans.

d

ND, not determined (fewer than 10 isolates).